Search - tctmd.com

Displaying 101 - 120 of 130

Sort: Relevancy | Date

News Daily News

MARIS Registry: Nitinol Stent Appears Safe, Effective in ‘Real World’ SFA Patients

October 03, 2014

Presentation TCT 2014

Case Presentation

Presenter: Sahil A. Parikh

September 17, 2014

Presentation TCT 2014

Master Class in SFA Technologies: Lining up the Data

Presenter: Robert M. Bersin, Dierk Scheinert, Roger Gammon, William A. Gray

September 13, 2014

News Daily News

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

May 30, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

January 22, 2014

News Daily News

Andamio Bioabsorbible Diseñado para el Manejo de la EAP Da Buenos Resultados Preliminares

January 22, 2014

News Daily News

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

L.A. McKeown

January 20, 2014

Presentation TCT 2013

SFA and Tibioperoneal Alternatives: Tailoring Therapeutic Choices

Presenter: Thomas Zeller

October 30, 2013

Presentation TCT 2013

Stenting Is the First-line Treatment for SFA Disease!

Presenter: J. Michael Bacharach

October 27, 2013

News Daily News

Patency Higher, Reintervention Lower with Stenting vs. Surgery in PAD

August 12, 2013

News Daily News

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

L.A. McKeown

November 25, 2012

News Daily News

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

L.A. McKeown

November 25, 2012

Presentation TCT 2012

SFA Intervention: State of the Art Today and in 2020

Presenter: Gary Ansel

October 24, 2012

Presentation TCT 2012

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Presenter: Eugenio Stabile

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

Presenter: Christopher Owens

October 22, 2012

Presentation TCT 2012

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

Presenter: Mark Burket

October 22, 2012

Presentation TCT 2012

Development of a Bioabsorbable Scaffold for the SFA

Presenter: Richard Rapoza

October 22, 2012

Advertisement

MARIS Registry: Nitinol Stent Appears Safe, Effective in ‘Real World’ SFA Patients

Case Presentation

Master Class in SFA Technologies: Lining up the Data

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

Andamio Bioabsorbible Diseñado para el Manejo de la EAP Da Buenos Resultados Preliminares

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

SFA and Tibioperoneal Alternatives: Tailoring Therapeutic Choices

Stenting Is the First-line Treatment for SFA Disease!

Patency Higher, Reintervention Lower with Stenting vs. Surgery in PAD

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

SFA Intervention: State of the Art Today and in 2020

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

Development of a Bioabsorbable Scaffold for the SFA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content